X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (640) 640
humans (580) 580
male (341) 341
female (290) 290
pharmacology & pharmacy (267) 267
piperazines - therapeutic use (256) 256
azabicyclo compounds (249) 249
hypnotics and sedatives - therapeutic use (232) 232
azabicyclo compounds - therapeutic use (231) 231
middle aged (229) 229
adult (226) 226
animals (187) 187
sleep initiation and maintenance disorders - drug therapy (181) 181
azabicyclo compounds - pharmacology (159) 159
aged (146) 146
piperazines - adverse effects (143) 143
hypnotics and sedatives - adverse effects (133) 133
double-blind method (124) 124
zopiclone (119) 119
insomnia (113) 113
azabicyclo compounds - adverse effects (98) 98
psychiatry (94) 94
neurosciences (90) 90
azabicyclo compounds - administration & dosage (82) 82
eszopiclone (81) 81
zolpidem (81) 81
ceftazidime - therapeutic use (80) 80
mice (80) 80
microbiology (79) 79
pyridines - therapeutic use (77) 77
treatment outcome (77) 77
piperazines - pharmacology (76) 76
anti-bacterial agents - therapeutic use (75) 75
clinical neurology (67) 67
rats (67) 67
sleep (67) 67
dose-response relationship, drug (66) 66
microbial sensitivity tests (64) 64
piperazines - administration & dosage (63) 63
benzodiazepines (62) 62
hypnotics (60) 60
young adult (59) 59
hypnotics and sedatives - pharmacology (58) 58
sleep - drug effects (58) 58
adolescent (57) 57
hypnotics and sedatives - administration & dosage (56) 56
efficacy (55) 55
drug therapy (52) 52
anti-bacterial agents - pharmacology (48) 48
azabicyclo compounds - chemistry (48) 48
azabicyclo compounds - pharmacokinetics (48) 48
infectious diseases (48) 48
pyridines - adverse effects (47) 47
double-blind (45) 45
pyrimidines - therapeutic use (44) 44
aged, 80 and over (43) 43
analysis (43) 43
clinical trials as topic (43) 43
time factors (43) 43
care and treatment (42) 42
drugs (42) 42
enterobacteriaceae (41) 41
benzodiazepines - therapeutic use (40) 40
beta-lactamase inhibitors - therapeutic use (40) 40
pharmacology (40) 40
acetamides - therapeutic use (39) 39
ceftazidime (39) 39
drug combinations (38) 38
ceftazidime - pharmacology (36) 36
medicine, general & internal (35) 35
pharmacology/toxicology (35) 35
chronic disease (34) 34
drug therapy, combination (34) 34
klebsiella-pneumoniae (34) 34
pseudomonas-aeruginosa (34) 34
safety (34) 34
abridged index medicus (33) 33
medicine & public health (33) 33
zaleplon (33) 33
article (32) 32
ceftazidime-avibactam (32) 32
rats, sprague-dawley (32) 32
research (32) 32
enterobacteriaceae - drug effects (31) 31
pharmacokinetics (31) 31
pyridines - pharmacology (31) 31
adults (30) 30
beta-lactamases - metabolism (30) 30
cross-over studies (30) 30
drug resistance, multiple, bacterial (29) 29
gram-negative bacterial infections - drug therapy (29) 29
klebsiella pneumoniae - drug effects (29) 29
pseudomonas aeruginosa - drug effects (29) 29
in-vitro activity (28) 28
piperazines - pharmacokinetics (28) 28
polysomnography (28) 28
toxicology (28) 28
avibactam (27) 27
benzodiazepines - adverse effects (27) 27
beta-lactamase inhibitors - pharmacology (27) 27
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (666) 666
German (16) 16
Russian (10) 10
French (5) 5
Dutch (2) 2
Finnish (2) 2
Danish (1) 1
Hungarian (1) 1
Japanese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 2016, Volume 538, Issue 7625, pp. 344 - 349
Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate whether... 
IN-VITRO | TRANSFER-RNA SYNTHETASE | MALARIA CONTROL | PLASMODIUM-FALCIPARUM | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | LIVER | TARGETS | PROTEIN-SYNTHESIS | NEXT-GENERATION | HEPATIC STAGES | Azabicyclo Compounds - pharmacology | Plasmodium falciparum - enzymology | Malaria, Falciparum - prevention & control | Male | Plasmodium falciparum - cytology | Azetidines - pharmacology | Plasmodium falciparum - drug effects | Cytosol - enzymology | Malaria, Falciparum - transmission | Liver - drug effects | Azabicyclo Compounds - chemical synthesis | Azabicyclo Compounds - therapeutic use | Female | Safety | Antimalarials - chemical synthesis | Disease Models, Animal | Life Cycle Stages - drug effects | Malaria, Falciparum - drug therapy | Azabicyclo Compounds - administration & dosage | Azetidines - adverse effects | Phenylurea Compounds - therapeutic use | Antimalarials - therapeutic use | Macaca mulatta - parasitology | Phenylalanine-tRNA Ligase - antagonists & inhibitors | Drug Discovery | Antimalarials - pharmacology | Animals | Azetidines - administration & dosage | Phenylurea Compounds - chemical synthesis | Antimalarials - administration & dosage | Azetidines - therapeutic use | Phenylurea Compounds - administration & dosage | Mice | Phenylurea Compounds - pharmacology | Liver - parasitology | Plasmodium falciparum - growth & development | Prevention | Antimalarials | Disease transmission | Health aspects | Transfer RNA | Proteins | Cytochrome | Malaria | Liver | Parasites | Kinases | Drug resistance | Drug dosages | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 11, pp. 1380 - 1389
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 09/2016, Volume 63, Issue 6, pp. 754 - 762
Background. The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE... 
acute pyelonephritis | ceftazidime-avibactam | complicated urinary tract infection | INFECTIOUS DISEASES | INITIAL ANTIBIOTIC-THERAPY | ANTIMICROBIAL THERAPY | MICROBIOLOGY | IMMUNOLOGY | INTRAABDOMINAL INFECTION | CARBAPENEM-RESISTANT ENTEROBACTERIACEAE | TREATMENT OPTIONS | BACTERICIDAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | SPECTRUM BETA-LACTAMASES | KLEBSIELLA-PNEUMONIAE | Doripenem | Azabicyclo Compounds - administration & dosage | Carbapenems - administration & dosage | Humans | Middle Aged | Male | Pyelonephritis - complications | Urinary Tract Infections - complications | Urinary Tract Infections - drug therapy | Carbapenems - adverse effects | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Ceftazidime - administration & dosage | Adult | Azabicyclo Compounds - therapeutic use | Female | Aged | Anti-Bacterial Agents - adverse effects | Ceftazidime - adverse effects | Pyelonephritis - drug therapy | Anti-Bacterial Agents - administration & dosage | Ceftazidime - therapeutic use | Drug Combinations | Azabicyclo Compounds - adverse effects | Care and treatment | Usage | Pyelonephritis | Clinical trials | Urinary tract infections | Influence | Dosage and administration | Ceftazidime | Antibiotics | Drug resistance | Drug therapy | CRE bacteria | Urinary tract diseases | Index Medicus | and Commentaries
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2016, Volume 60, Issue 10, pp. 6234 - 6243
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2018, Volume 61, Issue 9, pp. 4067 - 4086
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2017, Volume 61, Issue 2
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 09/2017, Volume 72, Issue 9, pp. 2616 - 2626
Objectives: The b-lactamase inhibitor relebactam can restore imipenem activity against imipenem nonsusceptible pathogens. Methods: To explore relebactam's... 
INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | ASIA-PACIFIC REGION | INITIAL ANTIBIOTIC-THERAPY | MICROBIOLOGY | INTRAABDOMINAL INFECTION | GRAM-NEGATIVE PATHOGENS | DISEASES-SOCIETY | IMIPENEM-CILASTATIN | PSEUDOMONAS-AERUGINOSA | PHARMACOLOGY & PHARMACY | BETA-LACTAMASE INHIBITOR | KLEBSIELLA-PNEUMONIAE | Imipenem - therapeutic use | Prospective Studies | Cilastatin - adverse effects | Humans | Middle Aged | Male | Gram-Negative Bacterial Infections - microbiology | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Azabicyclo Compounds - therapeutic use | Female | Urinary Tract Infections - microbiology | Anti-Bacterial Agents - adverse effects | Cilastatin - therapeutic use | Pyelonephritis - drug therapy | Drug Therapy, Combination | Azabicyclo Compounds - adverse effects | Imipenem - administration & dosage | Double-Blind Method | Cilastatin - administration & dosage | Azabicyclo Compounds - administration & dosage | Gram-Negative Bacterial Infections - drug therapy | beta-Lactamase Inhibitors - administration & dosage | Urinary Tract Infections - drug therapy | Administration, Intravenous | beta-Lactamase Inhibitors - adverse effects | beta-Lactamase Inhibitors - therapeutic use | Adolescent | Aged | Anti-Bacterial Agents - administration & dosage | Drug Combinations | Imipenem - adverse effects | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2015, Volume 59, Issue 10, pp. 5903 - 5908
New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with... 
URINARY-TRACT-INFECTIONS | THERAPY | IMIPENEM | EFFICACY | BETA-LACTAMASE | CEFTAZIDIME-AVIBACTAM | BLOOD-STREAM | REGIMEN | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | OUTCOMES | ENTEROBACTERIACEAE | Klebsiella pneumoniae - drug effects | Klebsiella Infections - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Minocycline - analogs & derivatives | Ganciclovir - analogs & derivatives | Colectomy | beta-Lactamases - biosynthesis | Intestine, Small - transplantation | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Minocycline - therapeutic use | Drug Resistance, Multiple, Bacterial | Ganciclovir - therapeutic use | Azabicyclo Compounds - therapeutic use | Colistin - therapeutic use | Female | Thienamycins - therapeutic use | Klebsiella Infections - drug therapy | Antiviral Agents - therapeutic use | Intestine, Small - microbiology | Bacteremia - drug therapy | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Klebsiella Infections - microbiology | Carbapenems - therapeutic use | Intestine, Small - drug effects | Klebsiella pneumoniae - enzymology | Klebsiella pneumoniae - growth & development | Bacterial Proteins - biosynthesis | Bacteremia - pathology | Ceftazidime - therapeutic use | Index Medicus | Challenging Clinical Cases in Antimicrobial Resistance
Journal Article